Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Fools Rush In: The Importance of Pre-Acquisition Due Diligence

July 29, 2014

Long before a deal is signed in ink, a company's compliance and legal team should be involved in the vetting process, writes Severin Wirz.

Pre-emption and States' Rights

July 23, 2014

Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.

Pharma MBAs — From Mini Courses to the Full Monty

July 23, 2014

John Ansell assesses the wide range of pharma MBA courses currently available, from the five-day "mini MBA" to year-long programs of study.

Breaking Point? The Escalating Costs of Oncology Care in the US

July 17, 2014

The US healthcare system will spend more than $150 billion on cancer by 2020. Daniele Severi Bruni, Jacob Schutz, and Anthony Hewitt ask if we have we have hit a breaking point in the escalating cost of oncology care.

Fixing the Disconnect in Medical Technology

July 16, 2014

The med-tech industry has a legacy of creating life-extending products while rewarding investors. This connection between innovation and profitability has been a key driver. But, writes Doug Mowen, change is underway.

Pharm Exec's 2014 Dealmakers Outlook

July 10, 2014

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

Vaccines: Fire in the Cold Chain

July 10, 2014

Its only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance.

WebMD: The Patient Value Equation

July 10, 2014

WebMD CEO David Schlanger tells PharmExec how connecting patients with physicians through a robust digital platform can deliver quality of care, cost savings, and better health outcomes.

The Peace Dividend

July 10, 2014

A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.

ADVERTISEMENT

Click here